Detail akcie Axim Biotech online

Business Summary: Axim Biotechnologies, Inc. develops and commercializes rapid, point-of-care diagnostic tests focused on ocular and systemic health. The Company's TearScan platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. The Company's product portfolio falls under the Eye Health sector and consists of the two FDA cleared 510(k) tests for dry eye disease (DED) and allergic conjunctivitis, both testing tears for these diseases. It has also internally developed an immunoassay for a potential third product which would measure MMP-9 in tears. MMP-9 is a biomarker for ocular surface inflammation and is an additional diagnostic tool for DED and other eye diseases. Its ophthalmological diagnostic tests include Ocular Immunoglobulin E (IgE) Test and Lactoferrin Test. IgE is a biomarker for allergic conjunctivitis, which often mimics dry eye disease or co-exists with dry eye disease.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Axim Biotechnologies Inc revenues increased from $17K to $70K. Net loss decreased 60% to $2.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Derivative Liability insufficient shares decrease from $3.7M (expense) to $0K, Interest Expense decrease of 58% to $342K (expense).